Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 27;15(1):119.
doi: 10.1186/s13019-020-01155-6.

Durability of bioprosthetic aortic valves in patients under the age of 60 years - rationale and design of the international INDURE registry

Bart Meuris  1 , Michael A Borger  2 , Thierry Bourguignon  3 , Matthias Siepe  4 , Martin Grabenwöger  5 , Günther Laufer  6 , Konrad Binder  7 , Gianluca Polvani  8 , Pierluigi Stefano  9 , Enrico Coscioni  10 , Wouter van Leeuwen  11 , Philippe Demers  12 , Francois Dagenais  13 , Sergio Canovas  14 , Alexis Theron  15 , Thierry Langanay  16 , Jean-Christian Roussel  17 , Olaf Wendler  18 , Giovanni Mariscalco  19 , Renzo Pessotto  20 , Beate Botta  21 , Peter Bramlage  21 , Ruggero de Paulis  22
Affiliations

Durability of bioprosthetic aortic valves in patients under the age of 60 years - rationale and design of the international INDURE registry

Bart Meuris et al. J Cardiothorac Surg. .

Abstract

Background: There is an ever-growing number of patients requiring aortic valve replacement (AVR). Limited data is available on the long-term outcomes and structural integrity of bioprosthetic valves in younger patients undergoing surgical AVR.

Methods: The INSPIRIS RESILIA Durability Registry (INDURE) is a prospective, open-label, multicentre, international registry with a follow-up of 5 years to assess clinical outcomes of patients younger than 60 years who undergo surgical AVR using the INSPIRIS RESILIA aortic valve. INDURE will be conducted across 20-22 sites in Europe and Canada and intends to enrol minimum of 400 patients. Patients will be included if they are scheduled to undergo AVR with or without concomitant root replacement and/or coronary bypass surgery. The primary objectives are to 1) determine VARC-2 defined time-related valve safety at one-year (depicted as freedom from events) and 2) determine freedom from stage 3 structural valve degeneration (SVD) presenting as morphological abnormalities and severe haemodynamic valve degeneration at 5 years. Secondary objectives include the assessment of the haemodynamic performance of the valve, all stages of SVD, potential valve-in-valve procedures, clinical outcomes (in terms of New York Heart Association [NYHA] function class and freedom from valve-related rehospitalisation) and change in patient quality-of-life.

Discussion: INDURE is a prospective, multicentre registry in Europe and Canada, which will provide much needed data on the long-term performance of bioprosthetic valves in general and the INSPIRIS RESILIA valve in particular. The data may help to gather a deeper understanding of the longevity of bioprosthetic valves and may expand the use of bioprosthetic valves in patients under the age of 60 years.

Trial registration: ClinicalTrials.gov identifier: NCT03666741 (registration received September, 12th, 2018).

Keywords: Aortic valve disease; INSPIRIS RESILIA; SAVR; Structural valve degeneration; Surgical aortic valve replacement; Valve durability.

PubMed Disclaimer

Conflict of interest statement

BM, RdP, TB, PB and MB have received lecture fees and/or research support from Edwards Lifesciences. The institutions of these and those of the remaining authors representing study centres have received patient inclusion-based funding. VG is an employee of Edwards Lifesciences. BB has no conflict of interest to disclose.

References

    1. Bhatia N, Basra SS, Skolnick AH, Wenger NK. Aortic valve disease in the older adult. J Geriatr Cardiol. 2016;13(12):941–944. - PMC - PubMed
    1. Eveborn GW, Schirmer H, Heggelund G, Lunde P, Rasmussen K. The evolving epidemiology of valvular aortic stenosis. The Tromso study. Heart. 2013;99(6):396–400. doi: 10.1136/heartjnl-2012-302265. - DOI - PubMed
    1. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years. Eur Heart J. 2016;37(34):2658–2667. doi: 10.1093/eurheartj/ehv580. - DOI - PubMed
    1. Kaneko T, Aranki S, Javed Q, McGurk S, Shekar P, Davidson M, Cohn L. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014;147(1):117–126. doi: 10.1016/j.jtcvs.2013.08.028. - DOI - PubMed
    1. Badhwar V, Ofenloch JC, Rovin JD, van Gelder HM, Jacobs JP. Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg. 2012;93(3):748–753. doi: 10.1016/j.athoracsur.2011.12.032. - DOI - PubMed

Associated data

Grants and funding